Castle Biosciences CEO Derek Maetzold sells USD 203,642 of common shares
Reuters2026/08/18 20:10- Castle Biosciences CEO Derek J. Maetzold sold 1,100 shares on Aug. 14, 2026 at USD 30.02.
- He exercised options for 1,100 shares at USD 2.39 on the same day.
- Directly held stake fell to 21,479 shares following the transactions.
- Trusts linked to Maetzold also sold shares at USD 30.02, including 2,714 shares in the Maetzold Descendants 2020 Trust.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic IPO Wealth Bonanza Sparks Battle: Goldman Sachs, Bank of America, and Others Compete for Employee Wealth Management Business
Anthropic's valuation has soared dramatically in a very short period, and some employees who have held equity for just two years may be facing wealth realization on a scale far beyond expectations. Wealth management professionals remarked, “It’s like winning the lottery.” Currently, Goldman Sachs, Bank of America, BNY Mellon, JPMorgan, and Wells Fargo have all reached out to Anthropic, aiming to establish long-term wealth management relationships with these newly wealthy tech elites at an early stage.
Titan Logix grants 750,000 stock options to CEO, CFO at $0.53 per share
SentinelOne Chief Accounting Officer Robin Tomasello disposes of USD 265,461 in common shares
Cemig names Marco Aurélio Vasconcelos CEO